ES2051686T3 - METHOD FOR PREPARING ANTIHEMOPHILIC FACTOR (AHF) FOR COLD PRECIPITATION AND FOR IMPROVING THE SOLUBILITY OF THE RECOVERED AHF PRODUCT. - Google Patents

METHOD FOR PREPARING ANTIHEMOPHILIC FACTOR (AHF) FOR COLD PRECIPITATION AND FOR IMPROVING THE SOLUBILITY OF THE RECOVERED AHF PRODUCT.

Info

Publication number
ES2051686T3
ES2051686T3 ES86115463T ES86115463T ES2051686T3 ES 2051686 T3 ES2051686 T3 ES 2051686T3 ES 86115463 T ES86115463 T ES 86115463T ES 86115463 T ES86115463 T ES 86115463T ES 2051686 T3 ES2051686 T3 ES 2051686T3
Authority
ES
Spain
Prior art keywords
ahf
cold precipitation
fibrinogen
fibronectin
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES86115463T
Other languages
Spanish (es)
Inventor
Maria Erlinda C Sarno
Clifford R Graf
Rodolfo A Vasquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25168481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2051686(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter International Inc filed Critical Baxter International Inc
Application granted granted Critical
Publication of ES2051686T3 publication Critical patent/ES2051686T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)

Abstract

An improved method of recovering antihemophilic factor (AHF) from cryoprecipitated blood plasma is provided. The improved method incorporates the addition of a calcium ion source during the step of cold precipitation of fibrinogen and fibronectin contaminants, as well as the addition of polyethylene glycol (PEG) at one of various stages of the recovery process. PEG may be added during the cold precipitation of fibrinogen and fibronectin, during the precipitation of AHF, or prior to the filtration of AHF solution. The method of the present invention results in a final AHF product having greatly increased solubility, higher specific activity, and lower fibrinogen and fibronectin content.
ES86115463T 1985-11-08 1986-11-07 METHOD FOR PREPARING ANTIHEMOPHILIC FACTOR (AHF) FOR COLD PRECIPITATION AND FOR IMPROVING THE SOLUBILITY OF THE RECOVERED AHF PRODUCT. Expired - Lifetime ES2051686T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79655985A 1985-11-08 1985-11-08

Publications (1)

Publication Number Publication Date
ES2051686T3 true ES2051686T3 (en) 1994-07-01

Family

ID=25168481

Family Applications (1)

Application Number Title Priority Date Filing Date
ES86115463T Expired - Lifetime ES2051686T3 (en) 1985-11-08 1986-11-07 METHOD FOR PREPARING ANTIHEMOPHILIC FACTOR (AHF) FOR COLD PRECIPITATION AND FOR IMPROVING THE SOLUBILITY OF THE RECOVERED AHF PRODUCT.

Country Status (9)

Country Link
US (1) US4739039A (en)
EP (1) EP0221566B1 (en)
JP (1) JPH0822879B2 (en)
AT (1) ATE79266T1 (en)
AU (1) AU6487286A (en)
CA (1) CA1293941C (en)
DE (1) DE3686390T2 (en)
ES (1) ES2051686T3 (en)
ZA (1) ZA868516B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8505882D0 (en) * 1985-03-07 1985-04-11 Central Blood Lab Authority Purification of blood coagulation factor viii
DE3806562A1 (en) * 1988-03-01 1989-09-14 Alpha Therapeutic Gmbh TWO CHAMBER SYRINGE WITH A FILLING OF ACTIVITY SENSITIVE HUMAN PROTEIN AS AN ACTIVE SUBSTANCE
EP0399321B1 (en) * 1989-05-24 1993-06-23 Miles Inc. Gel filtration of heat treated factor viii
DE3926034C3 (en) * 1989-08-07 1996-11-21 Behringwerke Ag Process for the preparation of a stable factor VIII
IT1248723B (en) * 1990-06-12 1995-01-26 Scalvo S P A PROCESS FOR THE PURIFICATION OF FACTOR VIII AND FACTOR VIII OBTAINED WITH SUCH PROCESS
US5259971A (en) * 1992-03-02 1993-11-09 Cryolife, Inc. Method of preparing fibrinogen
US5330974A (en) * 1993-03-01 1994-07-19 Fibratek, Inc. Therapeutic fibrinogen compositions
US5523893A (en) * 1994-08-24 1996-06-04 Northrop Grumman Corporation Strain free temperature-compensated optical mounts
GB9424732D0 (en) * 1994-12-08 1995-02-08 Common Services Agency Heat treated blood plasma proteins
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
DK2193809T3 (en) 1999-02-22 2015-05-26 Univ Connecticut The albumin-free Factor VIII formulation
MX339060B (en) 2008-11-07 2016-05-09 Baxter Int Factor viii formulations.
CN106029690B (en) 2013-10-18 2021-08-31 诺瓦塞浦加工有限公司 Protein purification

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE713764A (en) * 1967-05-01 1968-09-16 Baxter Travenol Lab
US3652530A (en) * 1967-08-28 1972-03-28 American Nat Red Cross Antihemophilic factor prepared from blood plasma using polyethylene glycol
GB1507198A (en) * 1974-04-12 1978-04-12 Squibb & Sons Inc Antihemophilic factor
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
CA1054052A (en) * 1976-08-14 1979-05-08 Edward Shanbrom Simplified method for preparation of high yield, high purity factor viii concentrate
US4104266A (en) * 1977-04-14 1978-08-01 American National Red Cross Method for preparation of antihemophilic factor
FR2460305A2 (en) * 1979-06-29 1981-01-23 Merieux Inst PROCESS FOR PREPARING A FACTOR VIII CONCENTRATE
US4289691A (en) * 1980-01-18 1981-09-15 The Canadian Red Cross Society Method of obtaining intermediate purity factor VIII
US4386068A (en) * 1980-02-26 1983-05-31 Cutter Laboratories, Inc. Antihemophilic factor concentrate and method for preparation
US4294826A (en) * 1980-05-07 1981-10-13 Armour Pharmaceutical Company Process for the preparation of highly purified antihemophilic factor
AT369263B (en) * 1980-08-27 1982-12-27 Immuno Ag METHOD FOR PRODUCING A FACTOR VIII (AHF) HIGH CONCENTRATE
US4406886A (en) * 1983-01-14 1983-09-27 University Patents, Inc. Purification of antihemophilia factor VIII by precipitation with zinc ions
DE3318521A1 (en) * 1983-05-20 1984-11-22 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München METHOD FOR PRODUCING AN ANTIHAEMOPHILIE FACTOR CONCENTRATE
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate

Also Published As

Publication number Publication date
DE3686390T2 (en) 1993-03-04
ZA868516B (en) 1987-08-26
ATE79266T1 (en) 1992-08-15
EP0221566B1 (en) 1992-08-12
AU6487286A (en) 1987-05-14
CA1293941C (en) 1992-01-07
JPS62181220A (en) 1987-08-08
US4739039A (en) 1988-04-19
EP0221566A3 (en) 1987-10-07
EP0221566A2 (en) 1987-05-13
JPH0822879B2 (en) 1996-03-06
DE3686390D1 (en) 1992-09-17

Similar Documents

Publication Publication Date Title
ES2051686T3 (en) METHOD FOR PREPARING ANTIHEMOPHILIC FACTOR (AHF) FOR COLD PRECIPITATION AND FOR IMPROVING THE SOLUBILITY OF THE RECOVERED AHF PRODUCT.
CA1074698A (en) Method of collecting anti-hemophilic factor viii from blood and blood plasma
DE69831684D1 (en) METHOD FOR PRODUCING VIRUS-FREE THROMBIN FOR PREPARING FIBRIN ADHESIVE FROM HUMAN PLASMA POOL
ATE276994T1 (en) METHOD FOR PURIFYING LACTIC ACID ON AN INDUSTRIAL BASIS
DE69002427D1 (en) METHOD FOR PRODUCING A CONCENTRATE OF FACTOR VIII - VON WILLEBRAND FACTOR COMPLEX OF BLOOD COagulation FROM FULL PLASMA.
IL122665A0 (en) Method and apparatus for inactivating contaminants in blood products
EP0125520A3 (en) A process and a plant for the recovery of one or more constituents from a gas mixture
ES477942A1 (en) Process for recovery of ethylene oxide containing low levels of aldehydic impurities
GR3026053T3 (en) Recovery of citric acid from impure process streams by addition of strong acids and salts thereof.
KR880000465A (en) Method of making pure albumin
SE8104482L (en) PROCEDURE FOR PREPARING A FACTOR VIII (AHF) HIGH CONCENTRATE
DE69311337D1 (en) Process for the purification of proteins
DE69010442T2 (en) Purification of 1,1-dichloro-1-fluoroethane.
FI915813A0 (en) Process for the extraction of naturally produced chymosin
FR2632302B1 (en) PROCESS FOR RECOVERING CITRIC ACID FROM A LIQUOR CONTAINING IT
GR3007446T3 (en)
EP0237981A3 (en) Process for producing a sterile preparation containing blood coagulation factor viii
ATE35533T1 (en) PROCESS FOR RECOVERING PURE BENZOIC ACID.
ES2125620T3 (en) ASSESSMENT PROCEDURE OF AN EFFLUENT LIQUID ACID CONTAINING HEAVY METALS.
DE69525948T2 (en) METHOD FOR RECOVERING CITRIC ACID
JPH0345080B2 (en)
TW254947B (en) An improved process for hemoglobin purification
ATE138046T1 (en) METHOD FOR REMOVAL OF DEPOSITED IMPURITIES IN AN ORGANIC STREAM TO PRODUCE PURE PHOSPHORIC ACID
JPS6236487B2 (en)
EP0238986A3 (en) Process for the production of a preparation of blood coagulation factor viii in a concentrated form

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 221566

Country of ref document: ES